Page last updated: 2024-11-07

2-acetyl-4(5)-tetrahydroxybutylimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-acetyl-4(5)-tetrahydroxybutylimidazole: contaminant/component of caramel coloring III; produces lymphopenia without toxic effects in rats and mice; prevents spontaneous and cyclophosphamide-induced diabetes in mice [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID108037
CHEMBL ID488336
SCHEMBL ID306015
SCHEMBL ID10040084
MeSH IDM0142836

Synonyms (47)

Synonym
94944-70-4
EC-000.1919
2-acetyl-4-tetrahydroxybutylimidazole
2-athbi
2-acetyl-4(5)-tetrahydroxybutylimidazole
ethanone, 1-(4-(1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)-, (1r-(1r*,2s*,3r*))-
CHEMBL488336 ,
bdbm50018269
1-[5-[(1r,2s,3r)-1,2,3,4-tetrahydroxybutyl]-1h-imidazol-2-yl]ethanone
2-acetyl-4-(1,2,3,4-tetrahydroxybutyl)imidazole
thi
2-acetyl-4(5)-(1,2,3,4-tetrahydroxybutyl)-imidazole
2-ACETYL-4(5)-(L(R),2(5),3(R),4-TETRAHYDROXYBUTYL)-IMIDAZOLE (THI)
unii-hw195j55g1
2-acetyl-4(5)-(1,2,3,4-tetrahydroxybutyl)imidazole
hw195j55g1 ,
gtpl6626
1-[4-[(1r,2s,3r)-1,2,3,4-tetrahydroxybutyl]-3h-imidazol-2-yl]ethanone
SCHEMBL306015
1-[4-(1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl]ethanone
1-[4-((1r,2s,3r)-1,2,3,4-tetrahydroxy-butyl)-1h-imidazol-2-yl]-ethanone
1-(4-((1r,2s,3r)-1,2,3,4-tetrahydroxybutv1)-1h-imidazol-2-yl)ethanone
1-(4-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone
SCHEMBL10040084
2-acetyl-5-(tetrahydroxybutyl)imidazole
HMS3648I14
2-acetyltetrahydroxybutylimidazole, (1r,2s,3r)-
ethanone, 1-(5-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)-
2-acetyl-4(5)-tetrahydroxybutylimidazole, (1r,2s,3r)-
2-acetyl-4(5)-tetrahydroxybutylimidazole, (1r,2s,3r)-(-)-
1-(5-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone
DTXSID20241695
2-acetyl-4-tetrahydroxybutyl imidazole
2-acetyl-4(5)-(l(r),2(5),3(r),4-tetrahydroxybutyl)imidazole
Q27088980
(1r,2s,3r)-2-acetyltetrahydroxybutylimidazole
SR-01000946375-1
sr-01000946375
ethanone, 1-[5-(1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl]-
1-[5-[(1r,2s,3r)-1,2,3,4-tetrahydroxybutyl]-1h-imidazol-2-yl]-ethanone
A1-50281
EN300-6734460
1-{5-[(1r,2s,3r)-1,2,3,4-tetrahydroxybutyl]-1h-imidazol-2-yl}ethan-1-one
HY-14113
CS-0003202
Z2044772905
AKOS040744434

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" An increase in dosage in two groups of mice, to 1000 and 2000 parts/10(6), resulted in marked lymphopenia."( Lymphopenic effects on mice of a component of ammonia caramel, 2-acetyl-4(5)-tetrahydroxybutylimidazole (THI).
Iscaro, A; Mackay, IR; O'Brien, C,
)
0.37
" 31 induces profound reduction of peripheral T cell numbers after oral dosage and confers pronounced protection in a rat model of multiple sclerosis."( Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis.
Beerli, C; Bergsdorf, C; Billich, A; Braendlin, N; Oberhauser, B; Schubart, A; Srinivas, H; Weiler, S, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
luteinizationSphingosine-1-phosphate lyase 1Homo sapiens (human)
vasculogenesisSphingosine-1-phosphate lyase 1Homo sapiens (human)
kidney developmentSphingosine-1-phosphate lyase 1Homo sapiens (human)
fatty acid metabolic processSphingosine-1-phosphate lyase 1Homo sapiens (human)
ceramide metabolic processSphingosine-1-phosphate lyase 1Homo sapiens (human)
spermatogenesisSphingosine-1-phosphate lyase 1Homo sapiens (human)
androgen metabolic processSphingosine-1-phosphate lyase 1Homo sapiens (human)
estrogen metabolic processSphingosine-1-phosphate lyase 1Homo sapiens (human)
post-embryonic developmentSphingosine-1-phosphate lyase 1Homo sapiens (human)
fibroblast migrationSphingosine-1-phosphate lyase 1Homo sapiens (human)
hemopoiesisSphingosine-1-phosphate lyase 1Homo sapiens (human)
sphingolipid catabolic processSphingosine-1-phosphate lyase 1Homo sapiens (human)
Leydig cell differentiationSphingosine-1-phosphate lyase 1Homo sapiens (human)
regulation of multicellular organism growthSphingosine-1-phosphate lyase 1Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwaySphingosine-1-phosphate lyase 1Homo sapiens (human)
skeletal system morphogenesisSphingosine-1-phosphate lyase 1Homo sapiens (human)
roof of mouth developmentSphingosine-1-phosphate lyase 1Homo sapiens (human)
face morphogenesisSphingosine-1-phosphate lyase 1Homo sapiens (human)
apoptotic signaling pathwaySphingosine-1-phosphate lyase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
protein bindingSphingosine-1-phosphate lyase 1Homo sapiens (human)
sphinganine-1-phosphate aldolase activitySphingosine-1-phosphate lyase 1Homo sapiens (human)
pyridoxal phosphate bindingSphingosine-1-phosphate lyase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
endoplasmic reticulumSphingosine-1-phosphate lyase 1Homo sapiens (human)
endoplasmic reticulum membraneSphingosine-1-phosphate lyase 1Homo sapiens (human)
endoplasmic reticulumSphingosine-1-phosphate lyase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID371976Volume of distribution in 129/SvEvBrd x C57BL/6 hybrid mouse2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.
AID371977Induction of lymphopenia in 129/SvEvBrd x C57BL/6 hybrid mouse assessed as change in circulating lymphocyte level at 30 mg/kg, po administered as single dose after 18 hrs by complete blood count analysis relative to control2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.
AID371968Induction of lymphopenia in 129/SvEvBrd x C57BL/6 hybrid mouse assessed as change in circulating lymphocyte level at 100 mg/kg, po administered as single dose after 18 hrs by complete blood count analysis relative to control2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.
AID371972Cmax in 129/SvEvBrd x C57BL/6 hybrid mouse2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.
AID371975Oral bioavailability in 129/SvEvBrd x C57BL/6 hybrid mouse at 1 mg/kg, iv and 10 mg/kg, po2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.
AID371966Reduction in sphingosine-1-phosphate lyase activity in mouse spleen at 100 mg/kg, po after 18 hrs by radioreceptor binding assay2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.
AID1152734Inhibition of S1PL (unknown origin)2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis.
AID371973Tmax in 129/SvEvBrd x C57BL/6 hybrid mouse2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.
AID371969AUC (0 to infinity) in 129/SvEvBrd x C57BL/6 hybrid mouse at 10 mg/kg, po2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.
AID371971Clearance in 129/SvEvBrd x C57BL/6 hybrid mouse at 1 mg/kg, iv2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.
AID371970Permeability across human Caco-2 cell membrane at 20 uM2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.
AID371967Increase in sphingosine-1-phosphate level in mouse spleen at 100 mg/kg, po after 18 hrs by radioreceptor binding assay relative to control2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.
AID371974Half life in 129/SvEvBrd x C57BL/6 hybrid mouse2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (42)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (16.67)18.7374
1990's17 (40.48)18.2507
2000's6 (14.29)29.6817
2010's12 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.98 (24.57)
Research Supply Index3.78 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other43 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]